Neurokinin 1 receptor antagonist along with dexamethasone reduces the inflammation in COVID-19 patients: a novel therapeutic approach

作者：Riffat Mehboob, Fridon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, Muhammad Akram Tariq, Shadi Tamur, Imran Shahid, Iman Mirza, Amany Fathaddin, Samy A. Abusikkuen, Mohamed A. Zayed · 发表于：Advancements in Life Sciences · 年份：2023 · DOI：10.62940/als.v10i3.1842 · 被引用次数：2 · 研究领域：COVID-19 Clinical Research Studies、Cancer, Stress, Anesthesia, and Immune Response、Pharmacological Receptor Mechanisms and Effects

Background: Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. The aim of this study was to evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in COVID-19 patients against the usual treatments as controls.Methods: It is a two-arm, open-label, randomized clinical trial that was carried out at Bahria International Hospital in Lahore, Pakistan. PCR-positive, hospitalized patients older than 18 years old, all sexes, and in the critical to life-threatening stage were included. 52 patients were placed in control group A and 67 patients were placed in intervention group B out of a total 119 patients who were randomly assigned to both arms. Before and after the intervention, lab tests were conducted in both groups. Aprepitant, a neurokinin-1 receptor antagonist, was additionally administered to the other arm while the other arm got standard therapy and care. Additionally, both groups received oral administration of the corticosteroid dexamethasone.Results: Patients in group A were on average 56.05 years old, compared to 58.1 years old in group B. There were 24 women in group A and 28 in group B, while there were 28 men and 39 women in group A. Group A had three critical cases, but group B had six. The reduction in C-reactive protein in the intervention group, improvement in platelet count in group B, and normalization of ferritin and LDH levels in group B all indicated decreased ...